RecruitingNot ApplicableNCT07382141

Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age


Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

400 participants

Start Date

Mar 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To test whether the implementation of new diagnostic techniques (ultrasonography, speckle tracking, vascular stiffness study, cardiac MRI, and histologic studies) allows in CAYA (Childern, Adolescents, and Young Adults) cancer survivors a more sensitive and earlier identification of cardiovascular damage resulting from antineoplastic therapy that develops either acutely or remotely after completion of antineoplastic therapy.


Eligibility

Min Age: 0 YearsMax Age: 18 Years

Inclusion Criteria1

  • Diagnosis of oncological pathology and need for antineoplastic treatment

Exclusion Criteria1

  • None

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEParameters of vascular stiffness

VICORDER© is a noninvasive, quick and painless technique to be able to assess vascular elasticity and consists of placing a few sphygmomanometers (the same ones used to measure blood pressure) for a few minutes


Locations(5)

IRCCS - AOU di Bologna -Policlinico di Sant'Orsola UOC Pediatria

Bologna, Bologna, Italy

IRCCS AOU di Bologna -Policlinico di Sant'Orsola UO Cardiochirurgia pediatrica e dell'età evolutiva

Bologna, Bologna, Italy

IRCCS AOU di Bologna -Policlinico di Sant'Orsola UO Oncoematologia Pediatrica

Bologna, Bologna, Italy

IRCCS AOU di Bologna Policlinico di Sant'Orsola UO Cardiologia Pediatria e dell'età evolutiva

Bologna, Bologna, Italy

IRCCS AOU di Bologna Policlinico di Sant'Orsola UO Radiologia, sezione Cardio-Toraco-Vascolare

Bologna, Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07382141


Related Trials